Dr. Hilary Cass, lead author of the 2024 independent review of UK gender-identity services for children, has justified conducting a randomised controlled trial of puberty blockers to address evidence gaps on long-term safety and effectiveness. The trial is framed as reducing overall harm by generating robust data for clinical decision-making. — Photo by Marta Branco on Pexels (Pexels License)
MD, MPH, PhD. Editor-in-Chief, Georgian Medical Journal (GMJ). Professor and Head, School of Public Health, David Tvildiani Medical University (DTMU), Tbilisi, Georgia. Chair, Public Health Institute of Georgia (PHIG). President, Accréditation Sans Frontières (ASF), Paris. Secretary/Treasurer, UEMS Section of Public Health. WHO Consultant, Health and Migration, Geneva. Former Member, UN Secretary-General's Independent Accountability Panel for Every Woman, Every Child, Every Adolescent (IAP-EWEC, 2016–2021). ORCID: 0000-0001-7609-4515.
